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PURPOSE. The development of a method for the sustained ele-
vation of intraocular pressure in experimental glaucoma based
on the anterior chamber injection of paramagnetic microbeads.
METHODS. Unilateral glaucoma was induced in adult male Nor-
wegian Brown rats by the injection of paramagnetic polysty-
rene microspheres. A handheld 0.45 Tesla magnet was used to
draw the beads into the iridocorneal angle to impede aqueous
drainage via the trabecular meshwork.
RESULTS. Elevated intraocular pressures (IOPs) were induced in
61 rats, resulting in a mean elevation of 5.8 mm Hg 1.0 (SEM)
relative to the contralateral control eye. The mean duration of
sustained IOP elevation (defined as 5 mm Hg relative to the
control eye for at least 7 consecutive days) after a single
injection was 12.8 days  0.9 (SEM, maximum duration 27
days). In all eyes, the visual axis remained clear from the time
of injection, with minimal inflammation after injection. Retinal
ganglion cell loss was determined in 21 animals (mean integral
IOP, 194.5 mm Hg days  87.5 [SEM]) as 36.4%  2.4 (SEM)
compared with the contralateral, untreated eye.
CONCLUSIONS. The use of paramagnetic microbeads for the oc-
clusion of the iridocorneal angle produces a sustained eleva-
tion of IOP with fewer injections and avoids the risk of visual
axis occlusion. It represents a simple and effective method for
the induction of experimental glaucoma. (Invest Ophthalmol
Vis Sci. 2011;52:1671–1675) DOI:10.1167/iovs.09-3921
Considerable advances have been made in our understand-ing of the pathophysiology of glaucoma, helped in part by
the availability of cost-effective models of disease based on
rodents, such as the rat and mouse.1,2 Although spontaneous
genetic models of glaucoma exist,3 the use of models in which
the precise onset of glaucoma can be determined is important
for grading diseases and the evaluation of novel therapies.
A variety of methods have been developed for the elevation
of intraocular pressure (IOP), each with advantages and disad-
vantages. For example, cautery of episcleral vessels,4–7 per-
haps the simplest method, runs the risk that it might create
venous drainage of the choroid and therefore induce retinal
effects unrelated to the elevation of IOP. Other methods, such
as episcleral vein sclerosis with hypertonic saline IOP8–10, limit
the outflow of aqueous at the level of the trabecular meshwork
to produce stable and moderate elevations of IOP with a low
risk of choroidal damage.11 However, the injections can be
technically challenging. As a result of these considerations,
alternative methods have been sought to induce experimental
glaucoma in rodents. Laser occlusion of the episcleral ves-
sels12–16 can be effective but works best with albino animals
and requires use of a laser facility. More recently, methods
based on obstruction of the trabecular meshwork with micro-
scopic beads have been used,7,17 after successful application of
this technique in primates.18 The injection of microbeads into
the anterior chamber is straightforward, does not require spe-
cialist equipment, and can be applied to a range of species with
only minor modification. Furthermore, the IOP elevation can
be modulated with subsequent injections. The principal disad-
vantage is that beads can be difficult to retain after injection,
resulting in a variable increase in IOP. The location of the beads
within the anterior chamber can also be difficult to control; if
beads locate to the pupillary zone, they can compromise fun-
doscopic monitoring of optic nerve damage.
To address these issues, we have developed a novel tech-
nique for the induction of ocular hypertension using paramag-
netic microbeads. The beads have the advantage that they can
be directed to the iridocorneal angle in the rodent eye to
optimize occlusion of the trabecular meshwork and facilitate
visualization of the fundus. Subsequent injections can be given,
as required, to further modulate the elevation in IOP.
MATERIALS AND METHODS
Induction of Elevated IOP
All experimental procedures complied with Home Office (UK) regula-
tions and the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research. Sixty-one retired male breeder Brown Norway
rats were housed in a constant low-light environment (40–60 lux) to
minimize diurnal fluctuations in IOP, with food and water provided ad
libitum. IOPs were measured three times before injection and daily or
every 2 to 3 days after injection using a rebound tonometer (TonoLab;
Tiolat, Oy, Finland) calibrated for use with the rat eye.19 All measure-
ments were made in awake animals in which the cornea was anesthe-
tized using topical 0.4% oxybuprocaine hydrochloride eye drops
(Chauvin, Kingston-Upon-Thames, UK). The IOP was taken as the
mean and SD of five readings.
In each animal, the IOP was elevated in the left eye by injecting a
sterile balanced salt solution (BSS; Alcon UK, Hemel Hempstead, UK)
containing 30 mg/mL ferro-magnetic microspheres (Corpuscular Inc,
Cold Spring, NY; bead diameter, 5 m) into the anterior chamber of
the left eye. Microspheres were sterilized by -irradiation (Gammacell
1000 Elite Caesium Source, 22 TBq; Nordon International, Inc., On-
tario, Canada). All injections were made under isoflurane anesthesia,
with topical chloramphenicol (0.5%) administered pre- and post-injec-
tion (Chauvin). Approximately 10–20 L was injected into the anterior
chamber of the left eye, delivering approximately 0.3–0.6 mg of beads.
The right eye acted as an unoperated control. Injections were made
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using a 32- or 33-gauge needle (Hamilton Corporation, Bonaduz, Swit-
zerland; and WPI Ltd, Stevenage, UK, respectively) inserted parallel to
the iris. The 33-gauge needles were beveled on three sides to facilitate
injection through the cornea and provided the easiest transit through
the corneal stroma. A tunneled injection was made with the needle
running parallel to the anterior surface of the iris to minimize the risk
of iris trauma. Since the beads tended to settle in the syringe under the
influence of gravity, the syringe and needle were agitated using a
vortex stirrer immediately before injection to resuspend the beads in
BSS. The minimum period between subsequent injections was 1 week.
Once the injection of beads was completed, the needle was kept in
position to ensure maintenance of anterior chamber depth, and the
beads then drawn away from the injection site using a small handheld
magnet (0.45 Tesla), thereby minimizing the egress of beads from the
injection track. The magnet was then used to distribute the micro-
spheres around the iridocorneal angle to reduce the outflow of aque-
ous humor via the trabecular meshwork. Immediate increases in IOP
could be moderated by allowing the leakage of aqueous around the
injection cannula as it was withdrawn from the eye. Attempts to do this
without redirection of beads resulted in the loss of beads via the
injection site. Microsphere injections were performed up to three
times in the left eye, depending on the required level and duration of
the IOP elevation. For the purposes of control studies, five rats were
injected with 20 L of magnetic microspheres without magnetic di-
rection to the iridocorneal angle. Five rats received a vehicle injection
of 20 L BSS (no beads) into the anterior chamber.
All rats were subsequently killed by an overdose of CO2 and
selected retinas prepared as whole mounts for the quantification of cell
loss in the retinal ganglion cell (RGC) layer. Anterior segment images of
the beads distribution were taken as required with a camera (Nikon
Coolpix 4500; Nikon, Tokyo, Japan) attached to a slitlamp (Haag Streit
UK Ltd, Harlow, UK). Cryosections (10 m) of the anterior chambers
prepared on gelatin-coated slides were stained with hematoxylin and
eosin for bright-field microscopic imaging or mounted under DPX
(Raymond A. Lamb) for DIC imaging. Section images were taken using
a bright-field microscope (Leica DMRA2; Leica Microsystems [UK] Ltd,
Milton Keynes, UK) and associated software (Leica QWin v.3; Leica).
Neuron Nuclei Imaging
For the quantification of RGC loss, retinal whole mounts were stained
(Hoechst 33342; Sigma-Aldrich, Gillingham, UK) and mounted in anti-
FIGURE 1. Magnet (large arrow) used to direct beads to the anterior
chamber angle. The smaller arrows show the location of beads in the
iridocorneal angle. Arrow a indicates beads adjacent to the magnet
that are being drawn into the angle. Arrow b shows the location of
beads contralateral to the magnet that were previously drawn into the
angle and remain in situ. Scale bar, 1 cm.
FIGURE 2. (A) Anterior segment im-
age showing the distribution of para-
magnetic beads immediately after mag-
netic redirection. Arrows indicate the
distribution of beads in the iridocor-
neal angle. After magnetic direction,
the beads become compacted into the
iridocorneal angle and are therefore
discernible as a band rather than as
individual beads. (B) Anterior segment
image showing the distribution of
paramagnetic beads without using a
magnet immediately post-injection. Ar-
rows indicate beads in the anterior
chamber angle and the iris surface, ex-
tending to the pupil. (C) Cryosection
of the anterior chamber injected with
magnetic beads showing complete oc-
clusion of the iridocorneal angle. The
eye was enucleated 32 days post-injec-
tion. The mean IOP increase for this
eye was 19.15 mm Hg. The integral
IOP increase was 470.83 mm Hg days.
AC, anterior chamber; MB, microbeads;
TM, trabecular meshwork. Inset image
shows higher magnification image of
the angle. The bead distribution is de-
marcated by the dashed line. (D) Cryo-
section of the anterior chamber from
the control eye.
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fade medium (ProLong Gold; Invitrogen Ltd, Paisley, UK). The number
of cells in the RGC layer was counted to provide an index of cell
damage. Although amacrine cells would have been included in the
analysis,20,21 this has been validated in the mouse glaucoma model as
a useful measure of RGC damage that avoids the variability associated
with RGC labeling.22
Images of the RGC layer were obtained using a fluorescent micro-
scope (Leica 6000B; Leica) linked to software (Stereo Investigator;
MicroBrightField, Magdeburg, Germany). Retinal specimens were
placed on a motorized stage, and the cells in the retinal ganglion cell
layer (RGCL) were imaged with a 20 objective in 12 fields (sample
area, 11,3095 m2) arranged in a grid centered on the optic nerve. The
number of labeled cells was counted manually (Cell Counter plug-in for
ImageJ; NIH Images, NIH, Bethesda, MD). Approximately 2.4% of the
total retinal area was sampled to estimate neuronal loss when com-
pared with the contralateral control eye. Standard morphologic criteria
were applied for discriminating nonneuronal cells (endothelial and
glial cells) from neuronal cells.
Statistics
Statistical analysis was performed using standard statistical software
(SPSS v.16.0 for Windows; SPSS, Chicago, IL). Normally distributed
data for the peak and integral IOP for the eyes with and without
hemorrhages were compared using independent-sample t-tests. IOP
measurements for single animals were expressed as mean  SD (SD).
Unless stated otherwise, group values were expressed as means and
standard errors of the mean (SEM). Pearson’s correlation coefficient
was used to test the correlation between peak IOP increase and cell
loss and mean IOP elevation and cell loss. The RGC layer counts in
control and experimental groups were compared using the indepen-
dent-sample t-test. The degree of cell loss in different retinal regions
was compared using a one-way ANOVA. Normally distributed data for
the mean IOP of the injected and contralateral eyes were compared
using independent-sample t-test.
RESULTS
IOP Elevation
Microbead injections were made in 61 rats. Figure 1 dem-
onstrates the technique for directing the microspheres to
the iridocorneal angle with the handheld external magnet.
The magnet strength was selected to exert local control
of the microbead distribution; beads lodged in the iridocorneal
angle opposite the magnet were not displaced. The typical
bead distribution after injection and redirection with the ex-
ternal magnet is shown in Figure 2A. With sufficient anterior
chamber depth, the beads could easily be directed to provide
uniform occlusion of the iridocorneal angle, a process facili-
tated by retention of the cannula in the anterior chamber
during bead redistribution. Histologic examination of the ante-
rior segment of the eye after a single intraocular bead injection
confirmed sequestration of the beads within the trabecular
meshwork (Fig. 2C) in contrast with an uninjected contralat-
eral eye (Fig. 2D).
Microbead injections were well tolerated and did not incite
a uveitic response. Localized iris hemorrhages were noted if
the tip of the injection cannula damaged superficial vessels, but
these were small and resolved within a few days. The IOP
profiles after injection could be classified either as a sustained
increase in IOP (Fig. 3A; 64% of eyes) or a fluctuating increase
(Fig. 3B; 36% of eyes). A sustained IOP increase (defined as an
elevation in IOP 5 mm Hg greater than the contralateral eye on
at least 7 consecutive days) was obtained in 64% of rats. The
mean duration for the IOP increase after a single injection was
12.8  0.9 days with a maximum duration of 27 days. Since a
7-to-14-day period was allowed to elapse after the fall in IOP (to
confirm that the fall in IOP was persistent) the mean time
between injections (26.9 days  5.4) exceeded the mean
duration of IOP increase. Up to three injections were made in
any single animal. Fifty-one animals received injections with 20
L, four with 10 L, and six with 15 L Injections were
repeated to prevent the IOP falling to within 5 mm Hg of the
contralateral control eye.
The mean IOP for all the animals was 29.4  0.9 mm Hg for
injected eyes and 23.6  0.4 mm Hg in the contralateral
untreated eyes (P  0.001). The mean and peak IOP increases
were 5.8  1.0 and 35.7  1.0 mm Hg, respectively, with a
mean integral IOP increase of 118.0  57.4 mm Hg days.
Animals were monitored for a mean interval for 74  5.4 days
(range 11 to 178 days) during which they were regularly
checked for signs of inflammation. The injection of the beads
did not result in any long-term inflammatory response.
Figure 4 shows the mean intraocular pressure (IOP) in
experimental and contralateral eyes in all experimental rats
during the first 42 days after injection. Eyes injected with 10 L
(n  12) or 20 L of beads (n  51) did not demonstrate a
significant difference in either the mean IOP increase (6.0 
1.5 vs. 6.2  1.2 mm Hg) or peak IOP (31.05  2.0 mm Hg vs.
35.8  1.2 mm Hg).
To monitor the effect of bead injections alone, beads were
injected (20 L, five animals) at the same concentration but not
manipulated under the control of a magnetic field. Aqueous
was allowed to egress after the injection to ensure that the IOP
was normalized. After injection, the majority of beads settled
on the inferior part of the anterior chamber, near the injection
FIGURE 3. IOPs after single bead injections followed by using a
magnet to direct beads to the anterior chamber angle in rats CR352 (A)
and CR355 (B). IOPs after a single bead injection without using a
magnet in rat CR461 showing the transient increase in IOP (C). Error
bars, SD; open symbols, injected eye; closed symbols, control eye.
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site (Fig. 2B). The remaining beads were spread around the
anterior chamber. The IOP was measured every third day and
the animals monitored for 2 weeks post-injection. Figure 3C
shows the mean IOP profile injected rats in this group. The IOP
in the bead group did not show a significant increase (mean
IOP 28.71 [4.88] injected eye versus 27.04 [4.07] control eye;
P  0.21). In a further five animals vehicle injections (20 L
BSS) were made unilaterally with normalization of the IOP
post-injection. We observed a slight increase in IOPs in the
injected eyes over the 2-week period (mean IOP 30.03 [3.20]
injected eye versus 26.06 [2.91] control eye; P  0.002).
Neuron Quantification in the RGCL
All retinas were dissected out and prepared as whole mount
preparations. We observed discrete (100 m) retinal hemor-
rhages in a peripapillary distribution in 5 of the 61 eyes. RGCL
neuronal populations were sampled in 21 animals with mean
IOP elevation 7.7 1.4 mm Hg and mean integral IOP 194.5
87.5 mm Hg days. The mean density of cells in the RGC layer
in control retinas was 4080  99 cells/mm2 and 2593  139
cells/mm2 in glaucomatous retinas, accounting for 36.4 2.4%
cell loss (P  0.002). In a linear regression analysis we did not
observe a significant relationship between the degree of cell
loss relative to the contralateral control eye for the duration of
IOP increase (r2 0.18, P 0.56), peak or mean IOP increase,
or area under the IOP curve. We did not observe a consistent
difference in retinal regions when samples were taken at 1, 2,
or 3 mm from the optic disc for the degree of loss (P  0.98,
one-way ANOVA; see Table 1). RGC quantification in the bead
(no magnetic manipulation) and BSS injection animals did not
show any significant difference from controls.
DISCUSSION
We describe a simple and effective method for the elevation of
IOP in the rat. The technique is notable in that it is technically
undemanding and provides a measure of control over the
distribution of beads within the anterior segment. The ability
to draw the beads away from the visual axis and to distribute
them around the iridocorneal angle cleared the visual axis to
facilitate examination of the retina and optic disc.
The principal finding of the present study is that fewer
injections may be required to achieve a sustained increase in
IOP compared with injections using nonmagnetic beads. Thus,
the injection of latex microspheres, in combination with hy-
droxypropylmethylcellulose or when given alone required six
to nine weekly injections, respectively, to achieve sustained
elevation in IOP.7 Similarly, eight to 10 injections were neces-
sary to produce a sustained IOP elevation that lasted up to 2
weeks in the primate18; for more prolonged IOP elevation in
the primate, as many as 20 bead injections were required to
maintain significant occlusion of the iridocorneal angle. In the
present study we achieved a sustained IOP increase in 64% of
animals after up to three injections, lasting on average 12.8 
0.9 days. The mean IOP in injected eyes in our model, 29.4 
0.9 mm Hg, was similar to the mean IOP seen eyes injected
with latex microspheres (28.1  0.7 mm Hg).7 We were
interested to note that the increase in IOP was not consistently
related to the volume of the bead injection. One likely expla-
nation is that the egress of aqueous seen after removal of the
needle tended to normalize the IOP regardless of the injection
volume. The present study used beads of approximately 5 m
diameter, which was smaller than the 10 m beads used in
previous studies.7,18 Recently the use of 15 m beads has been
reported to achieve sustained IOP elevations of up to 8 weeks
based on two injections in rats, suggesting that the use of larger
beads may be important in the long-term induction of ocular
hypertension.17 The bead diameter of 5 m was selected
because this seemed most likely to occlude the spaces reported
in the rodent trabecular meshwork.23 In preliminary experi-
ments, the use of beads in the 1–2 m range did not produce
a consistent increase in IOP and had the disadvantage that the
beads were more difficult to guide in the anterior chamber. A
critical technical point is that we removed the carrier fluid in
which the beads are packaged to minimize the introduction of
potentially toxic agents into the anterior chamber.
For animals in which beads were not redirected, we did not
observe a significant, sustained elevation in IOP. Even in the
animals injected with 20 L of beads we did not observe a
significant reduction in RGC layer cell density compared with
animals with a sustained elevation in IOP. Taken together,
these observations suggest that the loss of cells in the RGC
layer results from the effects of sustained IOP increase, rather
than from any transitory increase in IOP as a result of injection.
The lack of RGC layer cell loss in the animal injected with BSS
alone is consistent with this conclusion.
The degree of cell loss in our model is similar to that
reported for other models. The use of (nonmagnetic) mi-
crobead occlusion in a rat glaucoma model7 produced a level
RGC loss (23.1 2.1%) similar to that seen in the present study
(36.4  2.4%). Comparable RGC loss (30%–40%) has also been
reported with the hypertonic saline model after moderate
elevation in IOP24,25and the episcleral vein cautery model
FIGURE 4. The mean IOP in all experimental rats during the first 42
days after injection. Error bars, SEM; open symbols, injected eyes;
closed symbols, control eyes.
TABLE 1. Cell Density, Mean Number of Cells per Retina, and Cell Loss in the RGCL for Control and Glaucomatous Retinas
Eccentricity
Control Retinas Glaucomatous Retinas
Percentage Cell Loss
(mean  SEM)
Cell Density
(cell/mm2  SEM)
Cell Count
(n  SEM)
Cell Density
(cell/mm2  SEM)
Cell Count
(n  SEM)
1 mm 4170  104 471  12 2701  14 305  14 35.2  2.5
2 mm 4327  98 489  11 2699  144 305  16 37.6  2.3
3 mm 3745  96 423  11 2381  145 269  16 36.4  2.6
Mean 4080  99 461  11 2593  139 293  16 36.4  2.4
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(30%–40%).5,26,27 We did not observe a consistent variation in
the degree of cell loss as a function of retinal eccentricity in the
sampled range (1–3 mm). By contrast, clustered RGC loss has
been reported in the rat vein cautery model.28 Other studies
have reported greater cell loss in the peripheral compared with
central regions, but in animals with longer durations of IOP;4
this pattern of cell loss has been observed in a comparative
study of bead injection, cautery, and hypertonic saline models,
with the greatest effect seen with vein cautery.7
In summary, we present a simple method for the induction
of experimental glaucoma in the rodent eye. It has the princi-
pal advantages over nonmagnetic microbead models in that the
visual axis is not obscured after injection and that complete
occlusion of the iridocorneal angle can be achieved with a
single injection. We anticipate that it could be adapted with
little modification for use in other species.
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